Daily Stock Analysis, ADRO, Aduro Biotech Inc, priceseries

Aduro Biotech Inc. Daily Stock Analysis
Stock Information
Open
6.10
Close
6.05
High
6.25
Low
6.00
Previous Close
6.10
Daily Price Gain
-0.05
YTD High
8.00
YTD High Date
Jan 5, 2018
YTD Low
5.83
YTD Low Date
Feb 9, 2018
YTD Price Change
-1.55
YTD Gain
-20.39%
52 Week High
14.05
52 Week High Date
Jul 25, 2017
52 Week Low
5.83
52 Week Low Date
Feb 9, 2018
52 Week Price Change
-5.75
52 Week Gain
-48.73%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Nov 13. 2017
8.25
Nov 28. 2017
8.79
10 Trading Days
6.60%
Link
Company Information
Stock Symbol
ADRO
Exchange
NasdaqGS
Company URL
http://www.aduro.com
Company Phone
510-848-4400
CEO
Stephen T. Isaacs
Headquarters
California
Business Address
740 HEINZ AVENUE, BERKELEY, CA 94710
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001435049
About

Aduro BioTech, Inc. operates as a clinical-stage immunotherapy company, which focuses on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Its technology platforms include LADD, STING Pathway Activator and B-select monoclonal antibodies. The company was founded in 2000 and is headquartered in Berkeley, CA.

Description

Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. It is developing CRS-207, which has completed Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer. The company is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract. In addition, it is developing STING Pathway Activator product candidates that are synthetic small molecule immune modulators, which target and activate Stimulator of Interferon Genes receptor under collaboration with Novartis Pharmaceuticals Corporation; and product candidates that address other therapeutic areas, such as autoimmune and infectious diseases. Further, the company's products pipeline comprises BION-1301, a B-select mAb novel therapy for multiple myeloma; and antibody product candidates, including APRIL for the treatment of multiple myeloma, as well as oncology therapies, such as CD27, PD-1, and CTLA-4. Aduro BioTech, Inc. has a collaboration agreement with Janssen Biotech, Inc. to develop drugs for the treatment of prostate and lung cancers; and development and commercialization agreement with Genmab to evaluate five bispecific antibody product candidates targeting immune checkpoints. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.